neuro: pd Flashcards
(43 cards)
3 cardinal signs
- Tremor :
- resting tremor (disappears with movement), increases with stress - Rigidity :
- ‘ratchet’-like stiffness (cogwheel rigidity); also leadpipe rigidity - Akinesia /bradykinesia :
-subjective sense of weakness, loss of dexterity, difficulty using
kitchen tools, loss of facial expression, reduced blinking, difficulty
getting out of bed/chair, difficulty turning while walking.
pathology
loss of dopaminergic neurons in substantia nigra
measuring PD
Hoehn and Yahr, staging
Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
non-motor sx
- cognitive impairment
- psychiatric sx: depression, psychosis
- sleep disorders
- autonomic dysfunction: constipation, gi motility, orthostatic hypoTN, sialorrhea
- fatigue
early/young onset PD
slower disease progression
features:
- less cognitive decline
- earlier motor complications
- dystonia is common initial presentation vs falls and freezing in late-onset
which drug used in preference for early/young onset PD?
dopamine agonists
predictors of more rapid course
- older onset and rigidity
- postural instability/ freezing gait
- dementia
- assoc comorbidities
- male sex
- poor levodopa response
no treatment of pd has been shown to be
neuroprotective
- goal of tx is to manage sx and function
- not to replace dopamine or cure PD
levodopa: w or wo food?
absorption decr w high fat or high protein meals
- separate adm by 2hr
why can’t dopamine be used as a treatment?
does not cross BBB
peripheral conversion of levodopa to dopamine
- catalysed by DOPA decarboxylase, MAO, COMT
- causes n/v, hypotension
Sinemet
1:4 or 1:10
carbidopa:levodopa
Madopar
1:10
beserazide:levodopa
onset of dyskinesia caused by levodopa
3-5yrs of initiating treatment
dose adj when switching from IR to CR levodopa
IR -> CR, incr dose by 25-50%
levodopa ddi
- antidopaminergics: metoclopramide, prochlorpherazine, antipyschotics
- iron, protein
- pyridoxine
dopamine agonists: ergot derivatives
bromocriptine, cabergoline, pergolide
lower F, due to extensive first-pass metabolism
dopamine agonists: non-ergot derivatives
ropinirole, pramipexole, rotigotine (transdermal), apomorphine (sc)
which dop agonist require dose adj for liver impairment?
ropinirole, mainly metabolised by the liver to inactive metabolites
which dop agonist require dose adj for renal impairment?
pramipexole, excreted largely unchanged in the urine
dop agonists adr
dopaminergic, peripheral: n/v, orthostatic hypoTN, leg edema
dopaminergic, central: hallucinations (usually visual > auditory), somnolence, day-time sleepiness, compulsive behaviours eg. gambling, shopping, eating, hypersexuality
non-dopaminergic: fibrosis, valvular heart disease
fibrosis, ergot or non-ergot DA higher risk?
ergot higher risk
- pulmonary, pericardic, retro-peritoneal
- may be partially reversible upon withdrawal
valvular heart disease, ergot or non-ergot DA higher risk?
incidence appears greater w ergot derived agents
when is DA preferred over levodopa?
younger patients, max treatment options and delay onset of levodopa-induced motor complications